Stocktoria
Arbutus Biopharma Corp ABUS
Arbutus Biopharma Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M |
| R&D expense | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M | $49.3M | $57.6M | $57.9M | $62.7M | $61.3M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M | -$57.8M | -$143.9M | -$89.8M | -$110.9M | -$491.6M |
| Interest expense | — | — | $459,000 | $1.7M | $2.9M | $4.0M | $2.1M | $226,000 | $261,000 | $0 |
| Income tax | $0 | $0 | $0 | $4.4M | $0 | $0 | -$12.7M | -$4.3M | -$24.3M | -$105.0M |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$76.2M | -$63.7M | -$153.7M | -$57.1M | -$84.4M | -$384.2M |
| EPS (diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | — | $-1.21 | $-1.56 | $-7.24 |
| Operating cash flow | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M | -$51.4M | -$71.0M | -$67.9M | -$48.6M | -$57.9M |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M | -$51.7M | -$71.6M | -$69.0M | -$55.9M | -$61.9M |
| Cash & equivalents | $18.0M | $36.3M | $26.3M | $30.8M | $109.3M | $52.3M | $31.8M | $36.9M | $54.3M | $23.4M |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M | $137.1M | $105.5M | $227.9M | $237.2M | $275.9M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M | $35.1M | $32.8M | $27.7M | $54.7M | $72.9M |
| Shareholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M | $102.0M | $72.7M | $200.2M | $182.5M | $203.0M |
Growth · year-over-year · Revenue CAGR 28.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +128.2% | -66.0% | -53.5% | +255.1% | +58.9% | +15.0% | +1.1% | -44.4% | +617.6% | -93.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.